Albert J Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4749311/publications.pdf Version: 2024-02-01



ALREDT | CHANC

#	Article	IF	CITATIONS
1	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. Brachytherapy, 2022, 21, 63-74.	0.5	3
2	Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. Clinical Genitourinary Cancer, 2022, 20, e94-e103.	1.9	1
3	Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost. Radiation Oncology, 2022, 17, 12.	2.7	2
4	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871.	7.1	18
5	Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer Journal of Clinical Oncology, 2022, 40, 517-517.	1.6	2
6	M2 macrophage increase in prostate adenocarcinoma after high-dose rate brachytherapy Journal of Clinical Oncology, 2022, 40, 271-271.	1.6	1
7	Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel. Frontiers in Oncology, 2022, 12, 853246.	2.8	3
8	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology, 2021, 4, 327-330.	5.4	3
9	Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. Radiation Oncology, 2021, 16, 99.	2.7	4
10	Payment Methodology for the Radiation Oncology Alternative Payment Model: Implications for Practices and Suggestions for Improvement. JCO Oncology Practice, 2021, 17, 761-764.	2.9	5
11	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12
12	Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs. Journal of Vascular and Interventional Radiology, 2021, 32, 1241.e1-1241.e12.	0.5	15
13	Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities. JCO Oncology Practice, 2021, 17, e1958-e1967.	2.9	19
14	High-Dose Rate Interstitial Spine Brachytherapy Using an Intraoperative Mobile Computed Tomography-Guided Surgical Navigation System. Operative Neurosurgery, 2021, 21, 507-515.	0.8	4
15	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. European Urology, 2020, 77, 201-208.	1.9	37
16	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiotherapy and Oncology, 2020, 151, 26-32.	0.6	19
17	Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications. Gynecologic Oncology, 2020, 159, 599-600.	1.4	1
18	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. Advances in Radiation Oncology, 2020, 5, 1334-1341.	1.2	1

Albert J Chang

#	Article	IF	CITATIONS
19	Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open, 2020, 3, e2017144.	5.9	6
20	The American Brachytherapy Society consensus statement on intraoperative radiation therapy. Brachytherapy, 2019, 18, 242-257.	0.5	53
21	Prostate-Specific Membrane Antigen Positron Emission Tomography–Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 261-262.	0.8	3
22	Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience. Brachytherapy, 2019, 18, 470-476.	0.5	10
23	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology, 2019, 125, 154-162.	1.0	20
24	Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy. Brachytherapy, 2018, 17, 259-264.	0.5	22
25	The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines. Journal of Clinical Oncology, 2018, 36, 3342-3344.	1.6	2
26	In Reply to Gensheimer and Trister. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1594-1596.	0.8	0
27	Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technology in Cancer Research and Treatment, 2017, 16, 178-187.	1.9	22
28	Respiration-Induced Intraorgan Deformation of the Liver: Implications for Treatment Planning in Patients Treated With Fiducial Tracking. Technology in Cancer Research and Treatment, 2017, 16, 776-782.	1.9	9
29	18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. Radiology, 2017, 282, 429-436.	7.3	15
30	Patterns of Local Failure following Radiation Therapy for Prostate Cancer. Journal of Urology, 2015, 194, 977-982.	0.4	39
31	Editorial Comment. Urology, 2014, 84, 1387-1388.	1.0	0
32	High-risk prostate cancer—classification and therapy. Nature Reviews Clinical Oncology, 2014, 11, 308-323.	27.6	340
33	Cautious Optimism for Extreme Dose Escalation in Prostate Cancer. European Urology, 2013, 64, 939-940.	1.9	1